Paloma Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Paloma Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,182	Closed	-$579K	–	2307
2020 Q4	$579K	Buy	+4,182	New	+$496K	0.02%	832
2020 Q1	–	Sell	-18,746	Closed	-$801K	–	1923
2019 Q4	$801K	Buy	+18,746	New	+$773K	0.01%	1097
2018 Q4	–	Sell	-4,494	Closed	-$343K	–	1692
2018 Q3	$343K	Buy	+4,494	New	+$366K	0.01%	1177
2018 Q2	–	Sell	-10,095	Closed	-$514K	–	2098
2018 Q1	$514K	Sell	10,095 -2,401	-19%	-$121K	0.01%	1356
2017 Q4	$580K	Buy	+12,496	New	+$613K	0.01%	1282
2016 Q3	–	Sell	-7,398	Closed	-$362K	–	2071
2016 Q2	$362K	Buy	+7,398	New	+$479K	﹤0.01%	1690

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Paloma Partners's RARE Position: Q1 2021 in Review

Paloma Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2021, closing a stake of 4,182 shares — an estimated $579K sold.

Paloma Partners first reported a position in RARE in Q2 2016 and held it in 6 quarters. The position peaked at $801K in Q4 2019. 255 funds tracked by Wall St. Rank hold RARE as of Q1 2021.

Paloma Partners reported no remaining Ultragenyx Pharmaceutical position as of Q1 2021 after selling out during the quarter.
Paloma Partners sold 4,182 Ultragenyx Pharmaceutical shares in Q1 2021, an estimated $579K.
Paloma Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and held it in 6 quarters.
Paloma Partners's Ultragenyx Pharmaceutical position peaked at $801K in Q4 2019.
255 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2021.

Based on Paloma Partners's 13F filing for Q1 2021, filed 17 May 2021.